NEO-ADIXERN (NEO-ADjuvant IXabepilone in ER-Negative Breast Cancer). A Feasibility Study of Dose-Dense FEC With G-CSF Support Followed by Dose-Dense Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in ER-Negative Breast Cancer.

Trial Profile

NEO-ADIXERN (NEO-ADjuvant IXabepilone in ER-Negative Breast Cancer). A Feasibility Study of Dose-Dense FEC With G-CSF Support Followed by Dose-Dense Ixabepilone With G-CSF Support as Neoadjuvant Chemotherapy in ER-Negative Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2014

At a glance

  • Drugs Ixabepilone (Primary) ; Cyclophosphamide; Epirubicin; Fluorouracil
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NEO-ADIXERN
  • Most Recent Events

    • 16 Nov 2011 Actual initiation date added 3 Jun 2008 as reported by European Clinical Trials Database.
    • 16 Nov 2011 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
    • 29 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top